Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...

People using weight loss medication have been told it's not a "quick fix" with many at risk of regaining their lost weight. Experts say successful weight management following a course of one of the ...

People using weight loss medication have been warned it is not a "quick fix" with many at risk of regaining their lost weight ...

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

People coming off obesity jabs like Wegovy and Mounjaro should have check-ups for at least a year to make sure they don't ...